Thus, future studies are warranted to confirm or disprove our observation of wild type reversion of IDH1 in recurrent gliomas that harbored IDH1- mutations in their primary tumor, to fully understand its importance for tumor maintenance and during tumor progression. Here, IDH1 is linked to central nervous system cancer.